title: In vivo effects of the anatoxin-a on striatal dopamine release.
abstract: Anatoxin-a is an important neurotoxin that acts a potent nicotinic acetylcholine receptor agonist. This characteristic makes anatoxin-a an important tool for the study of nicotinic receptors. Anatoxin-a has been used extensively in vitro experiments, however anatoxin-a has never been studied by in vivo microdialysis studies. This study test the effect of anatoxin-a on striatal in vivo dopamine release by microdialysis.The results of this work show that anatoxin-a evoked dopamine release in a concentration-dependent way. Atropine had not any effect on dopamine release evoked by 3.5 mM anatoxin-a. However, perfusion of nicotinic antagonists mecamylamine and alpha-bungarotoxin induced a total inhibition of the striatal dopamine release. Perfusion of alpha7*-receptors antagonists, metillycaconitine or alpha-bungarotoxin, partially inhibits the release of dopamine stimulated by anatoxin-a. These results show that anatoxin-a can be used as an important nicotinic agonist in the study of nicotinic receptor by in vivo microdialysis technique and also support further in vivo evidences that alpha7*nicotinic AChRs are implicated in the regulation of striatal dopamine release.
authors.affiliation: Department of Functional Biology and Health Sciences, Faculty of Biology, University of Vigo, Pontevedra, Spain. fcampos@uvigo.es
authors.forename: F
authors.initials: F
authors.lastname: Campos
authors.forename: R
authors.initials: R
authors.lastname: Durán
authors.forename: L
authors.initials: L
authors.lastname: Vidal
authors.forename: L R F
authors.initials: LR
authors.lastname: Faro
authors.forename: M
authors.initials: M
authors.lastname: Alfonso
mesh_terms: D000157:Aconitine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D002038:Bungarotoxins / Q000378:metabolism / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D000087522:Cyanobacteria Toxins; D004298:Dopamine / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D008464:Mecamylamine / Q000378:metabolism / Q000494:pharmacology; D017551:Microdialysis; D018722:Nicotinic Agonists / Q000378:metabolism / Q000494:pharmacology*; D018733:Nicotinic Antagonists / Q000378:metabolism / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011978:Receptors, Nicotinic / Q000378:metabolism; D014326:Tropanes / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D002038:Bungarotoxins; D000087522:Cyanobacteria Toxins; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D011978:Receptors, Nicotinic; D014326:Tropanes; C054634:methyllycaconitine; D008464:Mecamylamine; C509783:anatoxin a; D004298:Dopamine; D000157:Aconitine